Compare SanDisk (SNDK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SanDisk vs Vertex Pharmaceuticals Incorporated — how do they compare? SanDisk trades at $1,760.89 (market cap $254.47B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: SanDisk is the larger of the two by market cap. Which is the better fit depends on your goals.
| SNDK | VRTX | |
|---|---|---|
Market Cap | $254.47B | $134.06B |
Sector | Technology | Health |
52-Week High | $2.34K | $557.96 |
52-Week Low | $73.92 | $376.62 |
Enterprise Value | $249.89B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNDK trades at $1,737.99, down 0.12% on the day, with a neutral technical signal. The stock has surged over 500% in 2026, driven by AI-driven memory demand, and is set to join the S&P 500. Recent quarters show strong EPS beats, with Q2 2026 actual EPS of $39.25 surpassing the $34.96 estimate. Fundamentals are mixed, with a net loss in 2025 but a projected profit margin of 56.46% for 2026, supported by high gross margins and robust ROE of 91.64%.
Outlook is bullish due to AI memory supercycle tailwinds and contracted revenue floors, but risks include volatility from insider selling and valuation concerns. Analysts are overwhelmingly positive, with 87.5% buy ratings and a consensus price target of $2,330, implying 34% upside. Investors should weigh high growth potential against execution risks in a cyclical sector.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SanDisk
Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.
Read more on SNDK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
